Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Annexon Biosciences

Annexon Biosciences
2011 FOUNDED
PRIVATE STATUS
Series C LATEST DEAL TYPE
$75M LATEST DEAL AMOUNT
12 INVESTORS
Description

Developer of novel therapeutics intended to treat neurodegenerative disorders. The company's therapeutics includes a pipeline of classical complement pathway inhibitors focused on therapies for complement-mediated loss of nerve connections in the brain as well as in retinal cells for the diseases like Alzheimer's disease Huntington's disease and glaucoma, enabling medical practitioners to protect patients from synapse loss and inflammatory nerve damage in brain and retinal cells.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 180 Kimball Way
  • 2nd Floor, Suite 200
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Annexon Biosciences’s full profile, request a free trial.

Annexon Biosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 19-Dec-2018 $75M 00000 00000 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series B) 23-Jun-2016 0000 0000 000.00 Completed Clinical Trials - Phase 1
4. Accelerator/Incubator 01-Jan-2015 0000 Completed Startup
3. Early Stage VC (Series A1) 15-Dec-2014 0000 0000 000.00 Completed Startup
2. Early Stage VC (Series A) $1000K $1000K 0000 Completed Startup
1. Seed Round 01-Jan-2011 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Annexon Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 16,398,995 $0.001000 $0.06 $1.05 $1.05 1x $1.05 11.65%
Series A 1,015,434 $0.001000 $0.98 $0.98 1x $0.98 0.72%
To view this company’s complete Cap Table, request access »

Annexon Biosciences Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Adage Capital Management Hedge Fund Minority 000 0000 000000 0
Bain Capital PE/Buyout Minority 000 0000 000000 0
Citadel Hedge Fund Minority 000 0000 000000 0
Satter Investment Management Other Minority 000 0000 000000 0
The Blackstone Group PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Annexon Biosciences Executive Team (6)

Name Title Board
Seat
Contact
Info
Douglas Love JD Chief Executive Officer, President & Board Member
Ted Yednock Ph.D Chief Scientific Officer & Executive Vice President

4 Former Executives

You’re viewing 2 of 6 executives. Get the full list »

Annexon Biosciences Board Members (12)

Name Representing Role Since Contact
Info
Campbell Murray MD Novartis Venture Fund Board Member 000 0000
Carol Gallagher New Enterprise Associates Board Member 000 0000
Douglas Love JD Annexon Biosciences Chief Executive Officer, President & Board Member 000 0000
Emmett Cunningham Ph.D Clarus Ventures Board Member 000 0000
Frank Torti MD New Enterprise Associates Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 12 board members. Get the full list »